About
Aitiologic develops a multi-modal liquid biopsy platform that analyzes genomic, epigenomic, and fragmentomic signals from cell-free DNA in blood to enable tissue-resolved diagnostics, initially focusing on first-trimester non-invasive prenatal testing and early risk stratification for preeclampsia.
Explore Aitiologic's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.